PPARG and obesity due to melanocortin 4 receptor deficiency: Experimental outcomes have demonstrated that PPARγ antagonists may have apotential role in the management of obesity and diabetes, as they have been shown to induce reductions in body weight andimprovements in insulin sensitivity [8-9,10].Therefore, it is of interest to identify novel bioactive compounds that can potentially be used as PPARγ antagonists to combatobesity associated diabetes.